BioCardia, Inc.: Diferență între versiuni
The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei BioCardia, Inc. listata cu simbolul US.BCDA ==Descriere companie== BioCardia, Inc. (www.biocardia.com) is a clinical-stage regenerative medicine company. It develops novel autologous and allogeneic therapeutics for cardiovascular and pulmonary diseases. Its CardiAMP Cell Therapy System (CardiAMP) is its lead therapeutic program being advanced for two clinical indications. This cell therapy system is comprised of a cell potency screening test, a poin...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
BioCardia, Inc. (www.biocardia.com) is a clinical-stage regenerative medicine company. It develops novel autologous and allogeneic therapeutics for cardiovascular and pulmonary diseases. Its CardiAMP Cell Therapy System (CardiAMP) is its lead therapeutic program being advanced for two clinical indications. This cell therapy system is comprised of a cell potency screening test, a point of care cell processing platform, and a biotherapeutic delivery system. It is an autologous cell therapy being advanced for two indications in pivotal clinical trials. The CardiAMP Heart Failure Trial is a pivotal Phase III trial, which is designed to provide the primary support for the safety and efficacy of the CardiAMP Cell Therapy System for heart attack (BCDA-01) indication. The CardiAMP Chronic Myocardial Ischemia Trial is a pivotal Phase III trial, which is designed to provide the primary support for the safety and efficacy of the CardiAMP Cell Therapy System for chronic myocardial ischemia (BCDA-02) indication. | BioCardia, Inc. (www.biocardia.com) is a clinical-stage regenerative medicine company. It develops novel autologous and allogeneic therapeutics for cardiovascular and pulmonary diseases. Its CardiAMP Cell Therapy System (CardiAMP) is its lead therapeutic program being advanced for two clinical indications. This cell therapy system is comprised of a cell potency screening [[test]], a point of care cell processing platform, and a biotherapeutic delivery system. It is an autologous cell therapy being advanced for two indications in pivotal clinical trials. The CardiAMP Heart Failure Trial is a pivotal Phase III trial, which is designed to provide the primary support for the safety and efficacy of the CardiAMP Cell Therapy System for heart attack (BCDA-01) indication. The CardiAMP Chronic Myocardial Ischemia Trial is a pivotal Phase III trial, which is designed to provide the primary support for the safety and efficacy of the CardiAMP Cell Therapy System for chronic myocardial ischemia (BCDA-02) indication. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||